Amylyx Pharmaceuticals, Inc. (AMLX)
| Market Cap | 2.93B+95.8% |
| Revenue (ttm) | n/a+100.0% |
| Net Income | n/a+18.9% |
| EPS | n/a+43.6% |
| Shares Out | 111.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 552,928.181 |
| Open | 27.01 |
| Previous Close | 27.43 |
| Day's Range | 26.06 - 27.27 |
| 52-Week Range | 10.83 - 41.14 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 52.20(+98.03%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About AMLX
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$AMLX stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in AMLX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by AMLX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
AMLX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New AMLX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to AMLX from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in AMLX
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $127.91M |
| IWMiShares Russell 2000 ETF | $74.95M |
| VXFVanguard Extended Market ETF | $38.81M |
| IWOiShares Russell 2000 Growth ETF | $26.56M |
| IBBiShares Biotechnology ETF | $22.04M |
| VTWOVanguard Russell 2000 ETF | $20.10M |
Estimated from each fund’s disclosed top holdings × AUM
AMLX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from AMLX’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score